Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

α-Synuclein pathology in the neostriatum in Parkinson’s disease

α-Synuclein pathology in the neostriatum in Parkinson’s disease We immunohistochemically examined the neostriatum from 25 patients with symptomatic and presymptomatic Parkinson’s disease (PD) with various degrees of Lewy body pathology, using anti-phosphorylated α-synuclein (αS) antibody. These patients were classified according to the PD staging proposed by Braak et al. (Neurobiol Aging 24:197–211, 2003): stage II (αS pathology confined to the medulla oblongata and pontine tegmentum), stage III (αS pathology confined to the brainstem), stage IV (limbic stage), and stages V and VI (neocortical stage). αS immunohistochemistry revealed neuronal and glial cytoplasmic inclusions and neuritic changes in the neostriatum. αS inclusions were found in the medium-sized neurons (GABAergic neurons that project to the globus pallidus) and large neurons (cholinergic interneurons); the former began to appear at stage III and the latter was noted at stages V and VI. Neuritic changes and glial inclusions also began to appear at stage III. The numbers of neuronal and glial inclusions, and the extent of neuritic changes, correlated with the PD stage (P < 0.001). These findings suggest that intrinsic neostriatal neurons degenerate through αS aggregation during PD progression. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Neuropathologica Springer Journals

α-Synuclein pathology in the neostriatum in Parkinson’s disease

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/synuclein-pathology-in-the-neostriatum-in-parkinson-s-disease-Q5ZeAhYuhX

References (41)

Publisher
Springer Journals
Copyright
Copyright © 2007 by Springer-Verlag
Subject
Medicine & Public Health; Pathology
ISSN
0001-6322
eISSN
1432-0533
DOI
10.1007/s00401-007-0316-4
pmid
18000672
Publisher site
See Article on Publisher Site

Abstract

We immunohistochemically examined the neostriatum from 25 patients with symptomatic and presymptomatic Parkinson’s disease (PD) with various degrees of Lewy body pathology, using anti-phosphorylated α-synuclein (αS) antibody. These patients were classified according to the PD staging proposed by Braak et al. (Neurobiol Aging 24:197–211, 2003): stage II (αS pathology confined to the medulla oblongata and pontine tegmentum), stage III (αS pathology confined to the brainstem), stage IV (limbic stage), and stages V and VI (neocortical stage). αS immunohistochemistry revealed neuronal and glial cytoplasmic inclusions and neuritic changes in the neostriatum. αS inclusions were found in the medium-sized neurons (GABAergic neurons that project to the globus pallidus) and large neurons (cholinergic interneurons); the former began to appear at stage III and the latter was noted at stages V and VI. Neuritic changes and glial inclusions also began to appear at stage III. The numbers of neuronal and glial inclusions, and the extent of neuritic changes, correlated with the PD stage (P < 0.001). These findings suggest that intrinsic neostriatal neurons degenerate through αS aggregation during PD progression.

Journal

Acta Neuropathologica – Springer Journals

Published: Nov 14, 2007

There are no references for this article.